Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart in Systemic Sclerosis
NCT07502105Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of genakumab in systemic sclerosis (SSc), sponsored by Tongji Hospital. Primary endpoint: Modified Rodnan Skin Score at 12 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07502105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502105.